Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06452160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Jun 2024 to Jun 27, 2024v3
  2. Study arms: 1 to 2
    • Eligibility criteria expanded, about 3 words
    • Study title shortened, about 3 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Trial Details
NCT Number NCT06452160
Lead Sponsor BridGene Biosciences Inc.
Conditions
(from sponsor)		 Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
Related terms Hemangioendothelioma, Epithelioid, Mesothelioma
Enrollment 103 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov